Navigation Links
HUYA Bioscience Int'l Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
Date:3/3/2008

Progress validates HUYA's innovative U.S./China pharmaceutical

co-development model

SAN FRANCISCO, March 3 /PRNewswire/ -- IBC Conference -- HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the completion of three Phase I clinical trial protocols in China of a promising anti-arrhythmic compound, HBI-3000 (Sulcardine sulphate). The data from the trials support a desirable safety profile at dose levels displaying indications of pharmacologic activity. HBI-3000 is being developed as a potential treatment for both atrial and ventricular arrhythmias.

Anti-arrhythmic drugs are used today to treat patients with atrial fibrillation (AF), a serious condition that afflicts 5.6 million Americans. Anti-arrhythmic agents have also been used for the treatment of ventricular arrhythmias, although most have failed to demonstrate a survival advantage, and in some cases carry significant safety risk.

The main concern with anti-arrhythmic drugs is an increased risk of sudden death (Torsade de Pointes) in patients with underlying organic heart disease such as coronary artery disease, prior history of myocardial infarction and heart failure. A large subset of individuals with atrial and ventricular arrhythmias suffers from these conditions, precluding treatment with most existing anti-arrhythmic drugs. Development of safe anti-arrhythmic agents for use in these patients is needed. Pre-clinical data developed by HUYA and its Chinese partner, along with the Chinese clinical trial data suggest that HBI-3000 may have safety advantages over other anti-AF agents and exhibits broad spectrum ion channel inhibition without pro-arrhythmic activity that suggests it may also be safer to use in treatment of ventricular arrhythmias.

According to Mireille Gingras, Ph.D., CEO of HUYA, "the progress on this exciting new compound validates the efficiency and effectiveness of our co-development model with our Chinese partners. With HBI-3000, for example, we will have the opportunity to collaborate with our Chinese partners on their Phase II trials, which will be valuable in the U.S. development process. We leverage the knowledge and experience of both teams -- in addition to existing Phase I data from China -- to streamline and optimize that process in both countries. Our model sets a new standard for integrated, China/U.S. pharmaceutical co-development."

HUYA's innovative co-development model

HUYA was one of the first companies to recognize the potential of China as a source for novel pre-clinical and clinical stage compounds and pioneered an innovative co-development model. HUYA partners with Chinese research institutions and pharmaceutical companies to leverage and extend their research efforts, accelerate development, and provide a bridge into the U.S. development process and the biopharma market.

This model contrasts with that of large pharmaceutical companies whose approach is to start their own research facilities in China hoping to tap its large biotech talent pool, or that of smaller competitors with "one-off" single compound strategies. With three strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA is uniquely positioned to identify and license novel Chinese compounds. Moreover, the strength of its relationships with its Chinese partners ensures a continuous source of these compounds for the future.

One of the key differentiators of HUYA's approach is the assembly of a world-class team of scientific and clinical advisors for each promising new compound, such as HBI-3000. This team collaborates with its Chinese partners and is then able to leverage and extend these efforts as the compounds enter the development process in the U.S, speeding the process and mitigating risk.

The U.S. advisors (announced in a separate release) for HBI-3000 comprise a world class team of scientists and clinicians including Benedict Lucchesi, Ph.D. MD, Peter R. Kowey, M.D., Dennis Roy, M.D., Jefferson L. Anderson, M.D., Eric J. Topol, M.D., and Stanley Nattel, M.D.

About HUYA

HUYA is the leader in U.S./China pharmaceutical co-development, formed to meet the global need for new, untapped sources of pre-clinical and clinical stage compounds. HUYA identifies the most promising new compounds in China and partners with Chinese research institutions to leverage and extend their research efforts, accelerate development, and provide a bridge into the U.S. development process and the biopharma market. With three strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA has pioneered the most innovative and productive approach for pharmaceutical co-development between the U.S and China. Further information about the company is available at http://www.huyabio.com.

Contact:

USA:

Jan Tuttleman, Ph.D.

Vice President, Marketing

HUYA Bioscience International

(858) 798-8800

jtuttleman@huyabio.com

China:

Wen Chen, M.S., MBA

EVP China Operation and Chief Representative

HUYA Bioscience International

86 (21) 51323312

wchen@huyabio.com

Media Contacts:

Amy Berry

(415) 793-2258

amyeberry@comcast.net

Juliet Travis

(510) 452-3771

juliet@travispr.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
2. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
5. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
6. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
7. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
10. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):